EU Politicians Squeeze Pharma Execs On Coronavirus Vaccine Contracts
Liability, Pricing & Access Under The Spotlight
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.
You may also be interested in...
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
A senior European Commission official has said that the first COVID-19 vaccinations are expected before the end of 2020, and confirmed that pharmaceutical companies developing vaccines will be liable for their products under existing laws.
A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.